Biological Assembly 1  

 3D View: Structure

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 16.60 kDa 
• Atom Count: 1160 
• Modelled Residue Count: 144 
• Deposited Residue Count: 144 
• Unique protein chains: 2

6MNL

NMR solution structures of second bromodomain of BRD4 with FOXO3a peptide

• DOI: 10.2210/pdb6MNL/pdb
• BMRB: 30373

• Classification: TRANSCRIPTION
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2018-10-02 Released: 2018-10-31 
• Deposition Author(s): Zeng, L., Zhou, M.-M.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Literature

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.

Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng, J., Stewart, R.L., Wang, C., Lin, P.C., Ghaffari, S., Evers, B.M., Liu, S., Zhou, M.M., Zhou, B.P., Shi, J.

(2018) Nat Commun 9: 5200-5200

• PubMed: 30518851 
• DOI: 10.1038/s41467-018-07258-y
• Primary Citation of Related Structures:  
  6MNL


• PubMed Abstract: 
  

BRD4 assembles transcriptional machinery at gene super-enhancer regions and governs the expression of genes that are critical for cancer progression. However, it remains unclear whether BRD4-mediated gene transcription is required for tumor cells to develop drug resistance. Our data show that prolonged treatment of luminal breast cancer cells with AKT inhibitors induces FOXO3a dephosphorylation, nuclear translocation, and disrupts its association with SirT6, eventually leading to FOXO3a acetylation as well as BRD4 recognition. Acetylated FOXO3a recognizes the BD2 domain of BRD4, recruits the BRD4/RNAPII complex to the CDK6 gene promoter, and induces its transcription. Pharmacological inhibition of either BRD4/FOXO3a association or CDK6 significantly overcomes the resistance of luminal breast cancer cells to AKT inhibitors in vitro and in vivo. Our study reports the involvement of BRD4/FOXO3a/CDK6 axis in AKTi resistance and provides potential therapeutic strategies for treating resistant breast cancer.

---

Organizational Affiliation: 

Guangdong Provincial Key Laboratory of Molecular Tumor Pathology, Southern Medical University, Guangzhou, Guangdong, 510515, China. [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
FOXO3a peptide	A	16	Homo sapiens	Mutation(s): 0  Gene Names: FOXO3, FKHRL1, FOXO3A
Find proteins for O43524 (Homo sapiens) Explore O43524  Go to UniProtKB:  O43524
NIH Common Fund Data Resources
PHAROS:  O43524 GTEx:  ENSG00000118689

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Bromodomain-containing protein 4	B	128	Homo sapiens	Mutation(s): 0  Gene Names: BRD4, HUNK1
Find proteins for O60885 (Homo sapiens) Explore O60885  Go to UniProtKB:  O60885
NIH Common Fund Data Resources
PHAROS:  O60885 GTEx:  ENSG00000141867

Small Molecules

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
ALY	A	L-PEPTIDE LINKING	C8 H16 N2 O3		LYS

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 
• OLDERADO: 6MNL Olderado

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2018-10-02 
• Released Date: 2018-10-31 
Deposition Author(s): Zeng, L., Zhou, M.-M.

Revision History  

• Version 1.0: 2018-10-31
  Type: Initial release
  
• Version 1.1: 2018-12-19
  Changes: Data collection, Database references